Unknown

Dataset Information

0

Antibody persistence 100 days following the second dose of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia.

ABSTRACT:

SUBMITTER: Tadmor T 

PROVIDER: S-EPMC8353933 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Six-month antibody persistence after BNT162b2 mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia.
| S-EPMC8500836 | biostudies-literature
Unknown Antibody persistence after pneumococcal conjugate vaccination in patients with chronic lymphocytic leukemia.
| S-EPMC6037466 | biostudies-literature
Unknown Chronic lymphocytic leukemia monitoring with a Lamprey idiotope-specific antibody.
| S-EPMC3888878 | biostudies-literature
Unknown Spike-antibody waning after second dose of BNT162b2 or ChAdOx1.
| S-EPMC8285117 | biostudies-literature
Unknown Antibody response after second BNT162b2 dose in allogeneic HSCT recipients.
| S-EPMC8277189 | biostudies-literature
Unknown Intragenic Variations in BTLA Gene Influence mRNA Expression of BTLA Gene in Chronic Lymphocytic Leukemia Patients and Confer Susceptibility to Chronic Lymphocytic Leukemia.
| S-EPMC5334439 | biostudies-literature
Unknown Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia.
| S-EPMC6768881 | biostudies-literature
Unknown Time to Second-line Treatment and Subsequent Relative Survival in Older Patients With Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
| S-EPMC5769450 | biostudies-literature
Unknown Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia.
| S-EPMC4011919 | biostudies-literature
Unknown Dose Intensive Rituximab and High-Dose Methylprednisolone in Elderly or Unfit Patients with Relapsed Chronic Lymphocytic Leukemia.
| S-EPMC6915691 | biostudies-literature